• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • OLINK Services
    • Biomarker Data Analyses
  • R&D
  • Products
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
    • Your Customized Kit
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media

FIRALIS is a biotechnology company located in the very heart of BioValley, on the true triple border of FR-DE-CH, only a few minutes walking distance to Basel, the pharmaceutical capital of Europe. 

0231024285274-three-countries-bridge-15853939010664.jpg

Three Countries Bridge (La passerelle des Trois Pays), world's longest single-span bridge (248 mt) dedicated to pedestrians and cyclists only, crossing Rhine between France (Huningue) and Germany (Weil am Rhein), within the metropolitan area of Basel (Switzerland).

Firalis creates novel values via biomarker discovery, development and regulatory qualification and brings to market biomarker-based diagnostic products. With a comprehensive expertise in the field, Firalis develops diagnostic kits and provides an extensive range of biomarker services; to improve therapeutic decisions as well as disease outcomes and patient comfort, finally to reduce healthcare costs at remarkable extents.

 

Activities of Firalis mainly but non-exclusively involve biomarkers of inflammatory disorders such as atherosclerosis, rheumatoid arthritis, rare/orphan diseases such as systemic or autoimmune vasculitis. A major part of our activities cover drug-induced organ injuries in particularly kidney, liver and vasculature, as major drug targets.

 

Firalis acquired its pioneering leadership in translational biomarkers to its unique network of clinicians and clinical centers of excellence that it built step by step, since 2008, thanks to many R&D consortia it coordinated, consisting partners from the European Academia (mostly University Hospitals), Big Pharma and other SME with complementary know-how. For numerous of its R&D projects, Firalis has been awarded with research and entrepreneurship awards as well as significant research grants which allowed us to conduct some of the largest clinical biomarker studies ever.

 

At Firalis, we exclusively invest on projects with highest potential of success, commercialize constantly new products, and target to launch a high-value in-vitro diagnostic kit of our own.

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE